Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral
therapy. N Engl J Med.1997;337:734-739.
Gulick RM, Mellors JW, Havlir D.
et al. Simultaneous vs
sequential initiation of therapy with indinavir, zidovudine, and
lamivudine for HIV-1 infection: 100 week follow-up. JAMA.1998;280:35-41.
Montaner JSG, Reiss P, Cooper D.
et al. A
randomized, double-blind trial comparing combinations of nevirapine,
didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA.1998;279:930-937.
Fischl M, Greenberg S, Clumeck N.
et al. Safety and
activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral
naïve subjects.In: Program and abstracts of the 12th World AIDS
Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract
Staszewski S, Morales-Ramirez J, Flanigan T.
et al. A
phase II, multicenter, randomized, open-label study to compare the
antiretroviral activity and tolerability of efavirenz (EFV) + indinavir
(IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV +
ZDV + 3TC at 24 weeks [DMP 266-006].In: Program and
abstracts of the 12th World AIDS Conference; June 28-July 3, 1998;
Geneva, Switzerland. Abstract 22336.
Renaud M, Ait HM, Katlama C.
et al. Dynamics of
CD4+ T cell recovery in a large cohort treated with highly
active antiretroviral therapy at advanced stages of HIV disease.In:
Program and abstracts of the 12th World AIDS Conference; June 28-July
3, 1998; Geneva, Switzerland. Abstract 41179.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled
trial of two nucleoside analogues plus indinavir in persons with human
immunodeficiency virus infection and CD4 cell counts of 200 per cubic
millimeter or less. N Engl J Med.1997;337:725-733.
Hogg RS, Heath KV, Yip B.
et al. Improved survival
among HIV-infected individuals following initiation of antiretroviral
Palella Jr FJ, Delaney KM, Moorman AC.
et al. Declining
morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Raboud JM, Montaner JSG, Conway B.
et al. Suppression
of plasma viral load below 20 copies/mL is required to achieve a
long-term response to therapy. AIDS.1998;12:1619-1624.
Montaner JSG, Raboud JM, Rae S.for the INCAS and
AVANTI Study Groups. Adherence to treatment increases duration of
virologic suppression regardless of pVL nadir.In: Program and
abstracts of the 38th Interscience Conference on Antimicrobial Agents
and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract
Carpenter CCJ, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1998: updated
recommendations of the International AIDS Society–USA Panel. JAMA.1998;280:78-86.
Carr A, Samaras K, Burton S.
et al. A syndrome of
peripheral lipodystrophy, hyperlipidaemia and insulin resistance in
patients receiving HIV protease inhibitors. AIDS.1998;12:F51-F58.
Carr A, Samaras K, Chisholm DJ, Cooper DA.Pathogenesis
of HIV-1-protease inhibitor-associated peripheral lipodystrophy,
hyperlipidaemia, and insulin resistance. Lancet.1998;351:1881-1883.
Wong JK, Hezareh M, Gunthard HF.
et al. Recovery of
replication-competent HIV despite prolonged suppression of plasma
Finzi D, Hermankova M, Pierson T.
et al. Identification of a reservoir for HIV-1 in patients on highly active
antiretroviral therapy. Science.1997;278:1295-1300.
Chun TW, Stuyver L, Mizell SB.
et al. Presence of an
inducible HIV-1 latent reservoir during highly active antiretroviral
therapy. Proc Natl Acad Sci U S A.1997;94:13193-13197.
Montaner JSG, Harris M, Mo T, Harrigan PR.Rebound of
plasma HIV viral load following prolonged suppression with combination
Montaner JSG, Hogg R, Raboud J, Harrigan R, O′Shaughnessy M.Antiretroviral treatment in 1998. Lancet.1998;352:1919-1922.
Cooper DA, Emery S.Therapeutic strategies for HIV
infection: time to think hard. N Engl J Med.1998;339:1319-1321.
Hall DB, Montaner JSG, Reiss P.
et al. Induction-maintenance antiretroviral therapy: proof of concept. AIDS.1998;12:F41-F44.
Reijers MH, Weverling GJ, Jurriaans S.
et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected
individuals: Amsterdam Duration of Antiretroviral Medication (ADAM)
Havlir DV, Marschner IC, Hirsch MS.
et al. Maintenance
antiretroviral therapies in HIV-infected subjects with undetectable
plasma HIV RNA after triple-drug therapy. N Engl J Med.1998;339:1261-1268.
Pialoux G, Raffi F, Brun-Vezinet F.
et al. A randomized
trial of three maintenance regimens given after three months of
induction therapy with zidovudine, lamivudine, and indinavir in
previously untreated HIV-1–infected patients. N Engl J Med.1998;339:1269-1276.